Breaking News
Get 50% Off 0
😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingPro CLAIM SALE
Close

Novartis AG ADR (NVS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Novartis ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
107.70 -1.03    -0.95%
23/07 - Closed. Currency in USD ( Disclaimer )
Pre Market
107.00
-0.70
-0.65%
7:07:18 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,319,473
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 107.23 - 108.15
Novartis ADR 107.70 -1.03 -0.95%

NVS Recent Sentiments

 
This page contains information on users’ sentiments for the Novartis AG ADR stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Jul 18, 2024 Karel Hykl   108.09 Jul 22, 2024 @ 108.20 +0.10%
Jul 18, 2024 Armando Alejandro...   107.83 Jul 22, 2024 @ 108.20 +0.34%
Jul 10, 2024 dryogesh kothari   108.93 -1.13%
Jul 08, 2024 Helio Alessandro...   108.21 Jul 15, 2024 @ 110.71 +2.31%
Jul 05, 2024 teddy caceres   107.71 -0.01%
Jun 26, 2024 Filip Malski   107.06 Jul 01, 2024 @ 106.58 -0.45%
Jun 12, 2024 תום וינפלד   106.00 Jun 17, 2024 @ 104.80 -1.13%
Jun 10, 2024 PAZ CATALAN   105.16 Jun 17, 2024 @ 104.80 -0.34%
Jun 03, 2024 Peter Akeyo   102.91 Jun 28, 2024 @ 106.46 +3.45%
Jun 03, 2024 محمد فتحى   103.07 Jun 28, 2024 @ 106.46 +3.29%
May 31, 2024 Christian Hoeller   103.04 Jun 21, 2024 @ 105.22 +2.12%
May 30, 2024 PAZ CATALAN   100.84 Jun 03, 2024 @ 103.05 +2.19%
May 24, 2024 James Workman   101.11 May 27, 2024 @ 100.53 -0.57%
May 20, 2024 Leo Buganè   103.40 May 20, 2024 @ 102.67 +0.71%
May 15, 2024 Guido EQ   103.09 Jun 07, 2024 @ 105.33 +2.17%
Apr 24, 2024 성수 강   97.91 May 17, 2024 @ 102.55 +4.74%
Apr 23, 2024 Jose Botanch   96.00 Apr 29, 2024 @ 97.39 -1.45%
Apr 22, 2024 Alexandre Delaroche   94.51 Apr 29, 2024 @ 97.39 -3.05%
Apr 16, 2024 Gerardo Vega   93.09 Apr 22, 2024 @ 95.73 +2.84%
Apr 11, 2024 Roberto Pietro Pepe   94.13 May 03, 2024 @ 97.25 +3.31%
Apr 09, 2024 Elyor Mahkamov   95.58 May 03, 2024 @ 97.25 +1.75%
Apr 04, 2024 sergio troiano   97.33 Apr 26, 2024 @ 97.44 +0.11%
Mar 19, 2024 Aleksej Turnsek   96.16 Apr 12, 2024 @ 93.53 -2.74%
Mar 06, 2024 Luis angel Rodriguez...   102.75 Mar 29, 2024 @ 96.73 -5.86%
Mar 06, 2024 Gyula Rácz   102.70 Mar 29, 2024 @ 96.73 -5.81%
Feb 28, 2024 Эдуард Болдырь   102.25 Mar 22, 2024 @ 96.21 -5.91%
Feb 26, 2024 Ilkin Besirov   103.24 Mar 22, 2024 @ 96.21 -6.81%
Feb 15, 2024 spoo ok   99.51 Mar 08, 2024 @ 100.73 -1.23%
Feb 07, 2024 arif yüce   103.57 Mar 01, 2024 @ 102.06 +1.46%
Feb 07, 2024 Luis angel Rodriguez...   104.02 Mar 01, 2024 @ 102.06 +1.88%
Jan 04, 2024 Mladen Tisljarec   105.48 Jan 08, 2024 @ 107.05 +1.49%
Jan 03, 2024 Rodrigo Correia   104.19 Jan 26, 2024 @ 107.16 +2.85%
Dec 21, 2023 david ma   98.13 Jan 12, 2024 @ 107.45 +9.50%
Dec 14, 2023 Maxim Hayan   98.78 Jan 05, 2024 @ 106.32 +7.63%
Dec 13, 2023 Fernando Carrillo   97.80 Dec 18, 2023 @ 98.35 +0.56%
Dec 04, 2023 Fim Gim   98.47 Dec 29, 2023 @ 100.97 +2.54%
Oct 13, 2023 Jakub Prášek   97.23 Nov 30, 2023 @ 97.03 -0.21%
Oct 10, 2023   97.74 Nov 30, 2023 @ 97.03 -0.73%
Oct 04, 2023 Thomas Gard   95.37 Nov 30, 2023 @ 97.03 +1.74%
Sep 15, 2023 Yanis Perea   103.08 Sep 15, 2023 @ 103.08 0.00%
Sep 14, 2023 songyao goh   101.88 Nov 30, 2023 @ 97.03 -4.76%
Aug 29, 2023 Russell Degioia   103.35 Nov 30, 2023 @ 97.03 -6.12%
Aug 18, 2023 LeonardPersin   101.17 Nov 30, 2023 @ 97.03 -4.09%
Aug 16, 2023 Victor Shnider   102.09 Aug 21, 2023 @ 101.02 +1.05%
Jul 25, 2023 Borja Larragan   105.02 Nov 30, 2023 @ 97.03 -7.61%
Jul 18, 2023 Umang Shah   103.37 Nov 30, 2023 @ 97.03 -6.13%
Jul 10, 2023 DowJonesDave   96.43 Jul 19, 2023 @ 103.60 -7.44%
Jun 15, 2023 David McClain   101.37 Nov 30, 2023 @ 97.03 -4.28%
Jun 13, 2023 Jorge Pena   99.60 Aug 16, 2023 @ 102.59 +3.00%
Jun 12, 2023 Maria Ma   99.79 Nov 30, 2023 @ 97.03 -2.77%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVS Comments

Write your thoughts about Novartis AG ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jonah Garber
Jonah Garber Aug 03, 2022 9:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NVS reported solid results for Q1 that included a 10% jump in sales for its top-selling Cosentyx psoriatic arthritis drug. With a diverse portfolio of pharmaceuticals and strong momentum in a down market, NVS is worth a look for many reasons
Jonathan Sanders
Jonathan Sanders Aug 03, 2022 9:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thanks in part to strong performance, this is one of a few stocks that has posted positive gains in 2022 despite headwinds elsewhere in the market.
Zoran Labus
Zoran Labus Mar 25, 2021 11:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
Pankaj Negi
Pankaj Negi Jan 20, 2021 1:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy
Pete Pete
Pete Pete Sep 30, 2020 12:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
stats con chris
stats con chris Jun 17, 2020 12:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
just to know. I'm lost.this is the company that bought the medicines company?
Kristof Mouton
Stoffel Sep 17, 2019 4:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
before investing in @novartis, read #teampia (twitter).
Kas Kas
KastKast Feb 07, 2019 2:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
154952291883003.jpg
sell 89 expecting 80 timeframe 5 days
Robin Hood
Robin Hood Sep 28, 2018 7:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Long ENDOCYTE... I work in the field
Episcopolian OptionTrader
Episcopolian1 Jul 19, 2017 11:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$NVS: Novartis AG Looking at All Options Including IPO for Alcon Unit.. This is HUGE catalyst for $NVS share holders!!!!!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email